Will PSMA-targeting diagnostics and therapeutics revolutionize Prostate Cancer care?

29 January, 2020

Prostate cancer (PC) is the fourth most common cancer worldwide, affecting approximately 1.3 million people, with approximately 1 in 9 men being diagnosed during their lifetime. Patients with localized disease typically respond well to surgery. Should the disease recur, patients are often treated…

CTAD Impressions: Is there finally going to be a disease modifying therapy approved for Alzheimer’s?

16 December, 2019

Biogen presented data at CTAD showing aducanumab met its primary endpoint in the discontinued phase 3 emerge trial at CTAD, and is now progressing through the regulatory process with the FDA There are currently no disease modifying therapies approved for Alzheimer’s Disease (AD). With no way of s…

Rapid Approvals & Innovative Approaches, But Which Sickle Cell Therapies Will Offer Real Benefits?

28 November, 2019

Sickle cell disease (SCD) currently effects 100,000 patients in the US and about 1 in every 365 Black or African-American births; historically unmet need has been incredibly high with only a narrow selection of largely ineffective therapies available. November 2019 however sees a changing of the…

Key Insights from ESMO 2019

03 October, 2019

One of the big stories featured the battle between the PARP inhibitors. In ovarian cancer, Phase III clinical trial readouts has got analysts guessing how GSK, AstraZeneca and AbbVie may play it out against each other in the first-line setting. However, with AstraZeneca’s PARP readout in pancreatic c…

Two’s a crowd and three’s a party – managing a drug franchise

18 September, 2019

Do brand teams dread the idea of a drug franchise? We know the successes are there for the taking but how do you get there and avoid the slip-ups? Holding an active portfolio of drugs in a therapy area can be considered a strength for a pharmaceutical company and this goes beyond access to…

Findacure Rare Disease Showcase

13 August, 2019

Whilst, the diagnosis of a condition, is difficult for every patient and their family, the diagnosis of a rare disease has significantly greater challenges. On average, it takes patients with rare diseases, five years to gain the correct diagnosis. During this time, they will likely be routed…

Bio Asia Taiwan 2019 Highlights

02 August, 2019

The larger size of BIO Asia 2019, compared to last year, highlighted the increasing importance that global pharma and MedDev are placing on Asian markets. The conference included presentations from more than 80 industry experts including those from Silicon Valley Bank, Amazon, NVIDIA, MSD, Amgen,…